Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan Approves Nesp “Biosame,” Eyes Riveted on December Listing
The Ministry of Health, Labor and Welfare (MHLW) on August 15 approved a slew of new generic drugs ahead of the next generic reimbursement listing in December, including a so-called “biosame” version of Kyowa Hakko Kirin’s flagship renal anemia drug…
To read the full story
Related Article
- Authorized Generics for Iressa, Urief to Join NHI Price List; Nesp Biosame Skips Listing
December 13, 2018
- Nesp Biosame to Hit Japan Market in July-September 2019
October 31, 2018
- Kyowa Kirin Mum on Listing Request Status for Nesp “Biosame”
August 24, 2018
- Nesp “Biosame” Could Hit Market as Early as December
August 17, 2018
- Daiichi Sankyo Espha Likely to Roll Out Urief, Iressa Authorized Generics: December Listing
August 16, 2018
REGULATORY
- Japan Eyes Spring 2027 Plan to Address Drug Discovery Workforce Needs
October 19, 2026
- Minister Lauds Stemirac after Panel Backs Full Approval
October 19, 2026
- CEA Expansion Could Make Drug Price Premiums a Liability: JPMA Official
October 16, 2026
- Nipro’s Stemirac Nears 1st Full Nod Conversion for Regenerative Therapy
October 16, 2026
- Japan Set to Compile Support Measures to Secure MCMs by Year-End
October 15, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…